First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations

RT @BMCMedicine: New findings from a phase I trial @PKU1898 by Xuan Wang and colleagues: selective MEK inhibitor HL-085 shows substantial c…

First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations. BMC Med https://t.co/LhaFMFcObL

First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations. https://t.co/KuLhHAYZO7 https://t.co/OZqgP4ZFww

RT @BMCMedicine: New findings from a phase I trial @PKU1898 by Xuan Wang and colleagues: selective MEK inhibitor HL-085 shows substantial c…